TOP TEN perturbations for 1553561_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553561_at
Selected probe(set): 1553561_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553561_at (1553561_at) across 6672 perturbations tested by GENEVESTIGATOR:

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):-2.053419
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

pioglitazone study 4 (1uM; 6h) / normal PBMC sample

Relative Expression (log2-ratio):-1.4994078
Number of Samples:5 / 5
Experimental pioglitazone study 4 (1uM; 6h)
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and cultured with pioglitazone. Freshly isolated PBMCs were cultured in RPMI/10% FBS in the presence of 1uM pioglitazone for 6 hours. ATC code:
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):-1.3774862
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dengue fever study 10 (DF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):-1.3076897
Number of Samples:3 / 5
Experimental dengue fever study 10 (DF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-0.8427458
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

necrotizing myopathy study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):0.83760595
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

systemic lupus erythematosus study 3 / normal blood sample

Relative Expression (log2-ratio):0.81655884
Number of Samples:89 / 30
Experimental systemic lupus erythematosus study 3
Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE).
Control normal blood sample
Blood samples from healthy individuals.

dupilumab study 1 (150mg; non-lesional) / atopic dermatitis study 9 (baseline; non-lesional)

Relative Expression (log2-ratio):0.7311187
Number of Samples:2 / 7
Experimental dupilumab study 1 (150mg; non-lesional)
Non-lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained after therapy with dupilumab (150mg / wk / 4wks). 150mg of dupilumab was given once a week as subcutaneous injection, 4 injections in total. The samples were obtained 1 week after the last dupilumab injection. Dupilumab is an anti IL-4R mAb. ATC code:---
Control atopic dermatitis study 9 (baseline; non-lesional)
Non-lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained before therapy with dupilumab (150mg / wk / 4wks).

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-0.70808125
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

necrotizing myopathy study 1 / dermatomyositis study 3

Relative Expression (log2-ratio):0.69351244
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control dermatomyositis study 3
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of dermatomyositis (DM).